Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp60175_8k.htm |
Exhibit 99.1
Press Release www.shire.com |
 |
Director/PDMR Share Dealings
September 30, 2015 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that Ordinary Shares (“Shares”) and American Depositary Shares (“ADSs”) of the Company, as set out below, have been acquired today for the Non-Executive Directors, being the part of their total fees that are paid in shares for the period of service from July 1 to September 30, 2015.
| Type of Security (1) | Number of Shares/ADSs | ||
| Dominic Blakemore | Shares | 129 | |
| Olivier Bohuon | Shares | 127 | |
| William Burns | Shares | 155 | |
| Dr. Steven Gillis | ADSs | 52 | |
| Dr. David Ginsburg | ADSs | 45 | |
| David Kappler | Shares | 151 | |
| Susan Kilsby | ADSs | 154 | |
| Sara Mathew | ADSs | 16 | |
| Anne Minto | Shares | 154 | |
(1) One ADS is equal to three Shares
The Shares and ADSs were acquired on the London Stock Exchange and NASDAQ respectively at £44.98 per Share and $204.1653 per ADS.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
| Investor Relations | ||
| Matthew Osborne | mattosborne@shire.com | +1 781 482 9502 |
| Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
www.shire.com